AI Article Synopsis
- - The UK government extended the interval between the first and second doses of the BNT162b2 vaccine to increase vaccination rates, and this study evaluated the immune response (antibody levels) from the first dose over eight weeks, considering factors like age and vitamin D levels.
- - Blood samples were taken from healthcare workers after receiving their first vaccine dose, showing that antibody levels peaked around 3.2 weeks post-vaccination and remained detectable at 8 weeks; younger individuals and those with higher vitamin D levels had stronger immune responses.
- - The findings suggest that age and adequate vitamin D status positively influence vaccine response, indicating that booster vaccination campaigns should consider vitamin D levels, especially following sun exposure or supplementation.
Article Abstract
Background: Most approved vaccines utilise a two-dose strategy. To enable larger groups of patients to receive the first dose, the UK government increased the gap between the two doses from three to twelve weeks. Here we report on the immunogenicity of the first dose, including effect of age and vitamin D status on these levels over an 8 week-period.
Methods: Blood samples were collected from healthcare workers (HCW) receiving their first BNT162b2 vaccine dose between January and February 2021. Antibody (Ab) production was measured, prior to and weekly for 4 weeks post immunization, and a final measurement was performed at 8 weeks. Serum vitamin D concentrations were also measured at baseline.
Findings: Immunization of 97 HCW induced an Ab response that peaked 3•2 weeks post immunization to decrease thereafter. Ab levels remained positive at 8 weeks. IgG peak concentration was negatively associated with age (β=-0•440, p<0.001). Response to immunization was also significantly affected by vitamin D status (p=0•022), on average 29•3% greater peak value in individuals with 25(OH)D>50nmol/L. No other variable showed significant effect.
Interpretation: The first dose of BNT162b2 produced Ab levels that remained positive after 8 weeks. Peak was greater in younger subjects and 25(OH)D>50nmol/L was beneficial. Booster campaigns should take into consideration vitamin D status which is at its highest following a period of sunshine exposure or following oral supplementation (400-1000IU daily).
Funding: Abbott Diagnostics Ltd supplied the kits used to quantify the anti-SARS -CoV-2 Spike IgG and technical support as well as provided financial support for sample collections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923881 | PMC |
| http://dx.doi.org/10.1016/j.retram.2022.103344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: In Alzheimer's disease (AD), histone acetylation is disrupted, suggesting loss of transcriptional control. Moreover, converging evidence suggests an age- and AD-dependent loss of transcription controlled by all-trans-retinoic acid (ATRA), the bioactive metabolite of vitamin A (VA). Antioxidant depletion causes oxidative stress (OS).
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
University of Southern Santa Catarina (UNESC), Criciuma, SC, Brazil.
Background: The increasing prevalence of neurodegenerative diseases, particularly among women post-menopause, is linked to the decline in 17 β estradiol (E2). Vitamin D deficiency, common in older individuals, exacerbates this risk due to its anti-inflammatory and neuroprotective properties. Hypovitaminosis D is associated with age-related conditions, including cognitive decline.
View Article and Find Full Text PDFClinical predictors of disease severity in oral lichen planus.
Clin Exp Dermatol
January 2025
Institute of Dentistry, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK.
Background: The limited understanding of factors influencing the disease progression of oral lichen planus (OLP) poses challenges in delivering effective and personalised treatment for this condition, known to increase the risk of oral cancer and adversely impact patient quality of life.
Objective: This study aimed to systematically identify clinical predictors of disease severity in OLP patients.
Methods: This cross-sectional and single-site prospective study was conducted between December 2021 and February 2024 in the Departments of Oral Medicine and Oral & Maxillofacial Surgery, Aberdeen Royal Infirmary.
Clinical Manifestations.
Alzheimers Dement
December 2024
Addis Ababa University, Addis Ababa, CA, Ethiopia; Global Brain Health Institute, University of California, San Francisco, CA, USA.
Background: Vitamin D deficiency is linked with the risk of developing dementia and Alzheimer disease. There is paucity of data on serum vitamin D level among patients from tropical countries such as Ethiopia. The objective of this study is to determine the prevalence of vitamin D deficiency and associated factors among Alzheimer disease and related dementia patients in Ethiopia.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
University of Kansas Medical Center, Kansas City, KS, USA.
Background: Alzheimer's Disease (AD) is a systemic metabolic disease with a variable number and type of clinical symptoms mostly impacting the brain. Skin carotenoid content (SCC) is an objective measure of carotenoid-containing fruit and vegetable intake that has been validated in diverse populations. Our previous findings suggest SCC scores differ between older adults with and without AD regardless of dietary intake of carotenoids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!